Go to
JCI Insight
About
Editors
Consulting Editors
For authors
Alerts
Advertising/recruitment
Subscribe
Contact
Current Issue
Past Issues
By specialty
COVID-19
Cardiology
Gastroenterology
Immunology
Metabolism
Nephrology
Neuroscience
Oncology
Pulmonology
Vascular biology
All ...
Videos
Conversations with Giants in Medicine
Author's Takes
Reviews
Reviews
View all reviews ...
Review Series
Gut-Brain Axis (Upcoming)
Tumor Microenvironment (Mar 2021)
100th Anniversary of Insulin's Discovery (Jan 2021)
Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
Latency in Infectious Disease (Jul 2020)
Immunotherapy in Hematological Cancers (Apr 2020)
Big Data's Future in Medicine (Feb 2020)
View all review series ...
Viewpoint
Collections
In-Press Preview
Commentaries
Concise Communication
Editorials
Viewpoint
Top read articles
Clinical Medicine
JCI This Month
Current issue
Past issues
What should define a SARS-CoV-2 “breakthrough” infection?
John S. Schieffelin, … , Elizabeth B. Norton, Jay K. Kolls
John S. Schieffelin, … , Elizabeth B. Norton, Jay K. Kolls
Published May 11, 2021
Citation Information:
J Clin Invest.
2021;
131(12)
:e151186.
https://doi.org/10.1172/JCI151186
.
View:
Text
|
PDF
Viewpoint
What should define a SARS-CoV-2 “breakthrough” infection?
Text
PDF
Abstract
Authors
John S. Schieffelin, Elizabeth B. Norton, Jay K. Kolls
×
Full Text PDF |
Download
(303.25 KB)
